Peritoneal dialysis (PD) as a modality is underutilized in most parts of the world today despite several advantages including the possibility of it being offered in the remotest of locations and being significantly more affordable than haemodialysis (HD) in most cases. In this article, we will compare the cost of HD and PD in several countries to demonstrate that PD is less than, or at least as expensive as, HD. A thorough literature survey of EMBASE and PUBMED was conducted; 78 articles which compared the annual PD and annual HD costs were finally selected. Careful attention was paid to the methodology followed by each study and the year it was published in. Our final calculations included 46 countries (20 developed and 26 developing). We found that the cost of HD was between 1.25 and 2.35 times the cost of PD in 22 countries (17 developed and 5 developing), between 0.90 and 1.25 times the cost of PD in 15 countries (2 developed and 13 developing), and between 0.22 and 0.90 times the cost of PD in 9 countries (1 developed and 8 developing). From our analysis, it is evident that most developed countries can provide PD at a lesser expense to the healthcare system than HD. The evidence on developing countries is more mixed, but in most cases PD can be provided at a similar cost where economies of scale have been achieved, either by local production or by low import duties on PD equipment.
A B S T R AC T
Peritoneal dialysis (PD) as a modality is underutilized in most parts of the world today despite several advantages including the possibility of it being offered in the remotest of locations and being significantly more affordable than haemodialysis (HD) in most cases. In this article, we will compare the cost of HD and PD in several countries to demonstrate that PD is less than, or at least as expensive as, HD. A thorough literature survey of EMBASE and PUBMED was conducted; 78 articles which compared the annual PD and annual HD costs were finally selected. Careful attention was paid to the methodology followed by each study and the year it was published in. Our final calculations included 46 countries (20 developed and 26 developing). We found that the cost of HD was between 1.25 and 2.35 times the cost of PD in 22 countries (17 developed and 5 developing), between 0.90 and 1.25 times the cost of PD in 15 countries (2 developed and 13 developing) , and between 0.22 and 0.90 times the cost of PD in 9 countries (1 developed and 8 developing). From our analysis, it is evident that most developed countries can provide PD at a lesser expense to the healthcare system than HD. The evidence on developing countries is more mixed, but in most cases PD can be provided at a similar cost where economies of scale have been achieved, either by local production or by low import duties on PD equipment.
I N T RO D U C T I O N
In 2008, there were ∼1.75 million patients worldwide who regularly received renal replacement therapy in the form of dialysis, of which 89% or ∼1.55 million were on haemodialysis (HD) and ∼11% or ∼197 000 patients were on peritoneal dialysis (PD). Out of the 197 000 patients on PD, ∼59% were receiving treatment in developing countries and the remaining 41% in developed countries. In the case of HD, nearly 62% of the patients were being treated in developed countries and the remaining 38% in developing countries [1] .
At the current level of technology, it is not unreasonable to consider HD and PD as clinically equivalent modalities when we consider the general population of end-stage renal disease (ESRD) patients, with similar survival rates at 6, 12, 24, 36, 48 and 60 months. This is confirmed by the United States renal data system (USRDS) 2012 Annual Report, which adjusted for all possible patient characteristics [2] including age, sex, race, ethnicity and primary diagnosis. The same report goes on to say that the quality of life of PD patients is at least as good as that of HD patients-if not better. In continuation, we will thus consider HD and PD as perfect substitutes from an economic standpoint.
There are several published articles which compare the annual per patient cost of PD with that of HD. In 2008, Just et al. [3] published a review article, which reported the ratio of HD to PD costs in various developing and developed countries. The article concluded that HD is a more expensive modality than PD in developed countries, but sufficient data were not available to make any generalizations about the costs in developing countries. In 2001, Li and Chow [4] highlighted that the cost of HD was generally greater than PD in the developed Asian countries, while the reverse was true in the case of developing Asian countries. In 2010, an article by Abu-Aisha and Elamin [5] examined the situation of PD in Africa; there were only a few countries in which PD was cheaper than HD, while in most African countries PD is as expensive as-or more expensive than-HD. The paper also highlighted that PD as a modality is still at very early stages of development in Africa.
The purpose of this article is to provide an insight on how PD compares with HD in terms of annual per patient costs in different parts of the world. For our purposes, PD includes both continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD), while HD includes either in-centre HD or hospital HD (but not home HD). We have made an effort to clearly differentiate between the various methodologies followed in estimating the costs by the studies we considered. The results are reported as the HD/PD ratio (the annual per patient cost of HD divided by the annual per patient cost of PD). For each country, we will also report the PD utilization rate, APD usage, PD per million population (PMP) rate and number of PD patients in 2008.
M AT E R I A L S A N D M E T H O D S
A thorough literature survey of EMBASE and PUBMED (between 1992 and January 2013) was conducted. Articles which contained the terms 'peritoneal dialysis or continuous ambulatory peritoneal dialysis' and 'renal dialysis or HD' and 'economics or health economics or cost or costs or expenditures' were included. Articles published as editorials, letters or conference abstracts were rejected. A total of 79 articles were finally included in our study. Table 1 is an exhaustive list of all these studies, categorized according to country.
It is believed that a reliable cross-country comparison of cost data is difficult to perform because therapies comprised of a different blend of services and products. We found that these concerns were further complicated by the variability of the data compared between individual reports and by incomplete transparency. There was no consistent method of capturing cost data as different investigators performed them at different times in different countries with different motives. In order to highlight such differences in methodology, we classified studies into three broad categories depending on the comprehensiveness of the cost analysis. The most important factors to consider in evaluating the studies in this regard are: (i) Did the authors include all possible economic implications of the therapy, or did they limit their scope to the basic treatment only? (ii) Did the authors adjust for patient characteristics in order to avoid the selection bias that is inherent to the choice of administering HD or PD, or not?
The three categories resulting from these considerations are:
(i) cost-benefit analyses, cost-effectiveness analyses or costutility analyses; (ii) cost identification analyses or synthesis studies or calculation of yearly cost using basic treatment only; (iii) reimbursement given for the therapy depending on standard tariffs.
It is important to note that Category 1 comprises of studies which take into account patient characteristics, and therefore, can be considered the most reliable estimates among these categories. Neither Category 2 nor Category 3 makes any allowances for heterogeneity in patient characteristics. Studies in the latter categories might not achieve the quality and depth of the former, since they consider a more restricted range of cost: in fact, they do not include costs due to hospitalization, complications, emergency medicines, transportation and so on. However, we would like to point out that not considering such dimensions leads to more conservative estimates of the cost advantage of PD over HD. Let us take transportation costs as an example: an HD patient is required to travel to a clinic or a hospital 13 times a month on average, while a PD patient does not need to travel as often. In this respect, an assessment limited to basic costs only will result in lower estimate of the difference between PD and HD costs.
Given the lack of consistency between reports, we decided to state our results using the ratio between the per patient annual cost of HD to that of PD; for example an HD/PD ratio of 1.50 signifies that HD is on average 50% more expensive than PD. This approach, which was followed by Just et al. [3] , has numerous advantages in an economic perspective: first of all, it avoids possible biases introduced by heterogeneity in currency, eliminating the need for conversion rates. Furthermore, currency values are influenced by inflating prices; by using the HD/PD cost ratio, we overcome the difficulties implied by adjusting for inflation.
Some countries had multiple studies conducted on PD and HD costs. To determine a single value of the HD/PD cost ratio for each country, we used the following method: (ii) Second, we only considered recent papers (a total of 40 out of 79), except for six countries including Canada, Sweden, Switzerland, the Netherlands, Denmark and Philippines (7 papers out of 79). (iii) Third, we calculated the average HD/PD ratio by taking the arithmetic mean of ratios when more than one observation remained for the same country.
In addition, in order to obtain an estimate of the prevalent HD/PD cost ratio for a number of countries for which we could not find any recently published literature or any reliable government agency to contact [which may otherwise be considered interesting because of their peculiarities, be it high PD patients adjusted for population (PD PMP) rates or renewed government policy for dialysis], we devised a mail survey to be administered to senior nephrologists in such countries. We were able to collect data from a total of eight countries. For an overview of the questionnaire, please refer to Appendix 1. The results of the survey process are detailed in Appendix 2. It should be noted that nephrologists were asked for their estimate of basic treatment costs, in order to avoid any possible bias that could arise by not considering patient characteristics; for this reason, they are comparable with a Category 2 type of study in the framework provided above. 
O R I G I N A L A R T I C L E
P D u n d e r u t i l i z e d d e s p i t e c o s t a d v a n t a g e 
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R E S U LT S
For the purpose of this paper, we have divided the world into six regions, i.e. North America, Latin America, Asia and Middle East, Africa, Europe and Pacific. A summary of all papers, including the estimate of HD/PD cost ratios, year of publication and type of methodology, is provided in Table 1 . Table 2 summarizes all the country-level data for the PD utilization rate, APD usage rate, PMP for PD and HD and total number of PD patients in 2008. Table 3 is the final list of our estimates of HD/PD cost ratios in 46 countries. We also included a visual summary of our results in the form of a map in Figure 1 . In the following, we present a brief examination of relevant factors, region by region. 
O R I G I N A L A R T I C L E
P D u n d e r u t i l i z e d d e s p i t e c o s t a d v a n t a g e Canada. In 2008, Canada had ∼4000 patients on PD, with a much higher PD penetration than the USA, amounting to 18% [1] . The overall dialysis PMP is 656, out of which PD PMP is 120 and HD PMP is 536. PD is also significantly less expensive than HD. All data on PD utilization rates, APD utilization rates, PMP rates of PD patients are taken from Jain et al 2012 [1] . Overall PMP and PMP of HD patients were calculated using the PD utilization and PD PMP data. Code used for APD usage: 1 ≤ 12.5%, 2 = 12.5-25%, 3 = 25-37.5%, 4 = 37.5-50%, 5 ≥ 50%. 
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O R I G I N A L A R T I C L E
A.N. Karopadi et al. Arranged by the year of most recently available data. The types of study are also given. Studies with CU/CE/CB methodology account for all possible costs and patient characteristics, studies with CI methodology account for all costs but not patient characteristics, studies with B only account for basic treatment costs without hospitalization and complications and studies with R methodology just show the reimbursement provided for the therapy. There are few countries in Latin and Central America that use PD in a majority of the cases. Some examples include Mexico, El Salvador and Guatemala, which have PD utilization rates of 66, 76.5 and 56% [1] , respectively. Costa Rica and Colombia also have much higher PD utilization rates than the world average, with 48 and 37% [1] , respectively. The Latin American region has the highest absolute number of patients on PD, surpassing Asia and North America. In general, PD tends to be very affordable in countries which have local manufacturing facilities for CAPD bags (such as Mexico). Overall dialysis PMP rates vary from ∼30 in Nicaragua to as high as 802 in Chile [1] . On average, this group of countries has an overall dialysis PMP of 377 (280 HD and 97 PD) and therefore a high PD utilization rate of 26% [7] .
PD utilization rates vary from as low as 5% in Germany to >20% in Scandinavian countries and in the Netherlands [1] . The reason for this variation is due to the fact that the reimbursement structures are very different from country to country. In France and Germany, the reimbursement for HD is significantly higher than the reimbursement for PD, while in Italy the reimbursement does not vary with the modality. The usage of APD is higher than in most parts of the world, and due to well-structured healthcare systems, hardly any outof-pocket payments are made towards dialysis treatment. On average, HD in Europe is significantly more expensive (by 30-60%) than PD. Overall dialysis PMP rates are relatively high, ranging from 322 in Finland to 819 in Greece.
Most countries in Africa are very new users of PD. Given that solutions are often imported, PD is more expensive than HD in most countries, and PD utilization rates are very low, with the exception of South Africa. Cost data (except Egypt and Nigeria) are taken from the paper by Abu-Aisha and Elamin [5] and a paper by Katz et al. [8] . A recent paper by Okpechi et al. [9] found that PD is significantly cheaper than HD in South Africa if locally manufactured solutions are used. However, the HD/PD ratio of 0.58 reported in this paper is calculated based on the use of imported solutions. India. Dialysis penetration in India is still very low, mostly due to its limited reimbursement structure. PD in India has become significantly more affordable after the emergence of local manufactures like J Mitra Pvt Ltd. India is the seventh country with the largest number of PD patients (6500), behind Mexico, USA, China, Brazil, Japan and South Korea.
Nepal. Nepal is a prime example of a country that cannot achieve economies of scale and cannot have local production of CAPD bags given its small PD patient population; as of December 2012, there were a total of 1000 HD patients and just 45 PD patients. The government has recently been able to overcome the country's inability to produce PD equipment locally by removing all import duties on CAPD bags. Nepal now acquires bags from Baxter India at a cost of about 330 Nepali Rupees per bag (a little under USD 4). This has made PD significantly less expensive than HD.
Bangladesh, Sri Lanka and Pakistan. The PD utilization rate in these countries is low mainly due to the fact that PD is significantly more expensive than HD. PD solutions are imported and the duty is high. Most patients on HD in these countries can afford just two sessions a week and several drop out due to prohibitive dialysis costs. Only a few patients in these countries are reimbursed and that too by private insurance companies. Combining the three countries, there was a total of just 325 patients on PD in 2008. Combined population is nearly 350 million, which implies a PD PMP rate of <1.
Indonesia. The HD/PD ratio is ∼1.03 [10] , indicating that HD and PD cost nearly the same. CAPD is offered only in a few centres in the country and is not completely covered by the health insurance scheme. The health insurance does not support most patients as it is primarily meant for government officials.
Thailand. Thailand has recently implemented a PD first policy, and PD utilization is growing rapidly. The total number of PD patients in 2008 was 1198, making up roughly 5.5% of all dialysis patients [1] . Thailand does not locally produce PD solutions, but is able to import solutions at low or no duty.
Malaysia. The overall PMP of Malaysia is an impressive 331 [1] which is comparable with PMPs of countries like the Netherlands, Sweden, Finland, Denmark and Switzerland. Like Thailand, Malaysia obtains its PD solutions at little or no duty and the government favours the use of PD.
Iran. The PD utilization rate is ∼7% and the total number of PD patients in 2008 was 1150 [11] . CAPD bags are manufactured by Samen Pharmaceuticals under the license of Baxter Healthcare Corporation. According to a paper by Najafi [11] in 2010, PD was reported to be cheaper than HD by at least 7.5% which indicates a HD/PD ratio of at least 1.08. Since 1995, CAPD use in Iran has been steadily increasing.
Turkey. According to a paper by Utas et al. [12] in 2008 and a paper by Erek et al. [13] in 2004, the HD/PD ratio in Turkey is ∼1. 16 . PD solutions are locally manufactured in Turkey by Eczacibasi-Baxter. In 2008, there were 5774 PD patients in Turkey [1] .
Korea. In Korea, the government reimburses 90% of the total cost of dialysis irrespective of the modality. The catheter insertion is done by a general surgeon in most of the cases. This can lead to a long wait before being initiated on PD and could be considered an important deterrent to PD utilization. Despite all this, the PD utilization rate is 19% as of 2008 [1] .
Taiwan. Over the last few years, an active effort has been taken by the Taiwanese government to reduce HD domination. In 2007 [14] , PD reimbursement was increased by 20% while that of HD was reduced by 5%. From 2003-2007, the number of PD patients increased by almost 20%, while the increase in the number of HD patients was only ∼5.5%.
Japan. Patients are reimbursed 100% by the government irrespective of the modality. The HD/PD ratio is ∼0.85 (Fukuhara et al. [15] ). There are some economic reasons for this value, which is low when compared with other developed countries; one reason could be the high cost of CAPD bags. PD penetration is also low, possibly explained by the fact that doctors receive an extra physician fee for prescribing HD, while there is no such fee in the case of PD. A paper by Kawaguchi [14] in 2007 argued that low PD penetration in Japan could be better justified by non-economic reasons rather than economic reasons. Some of the non-economic reasons are lack of information and knowledge about PD among patients, lack 
P D u n d e r u t i l i z e d d e s p i t e c o s t a d v a n t a g e of PD education for doctors, unwillingness by the patient or the family to self-treat, desire to avoid complicated exchange procedures, lack of guarantee for extended use of peritoneal membrane as a dialyser, fear of peritonitis and encapsulating peritoneal sclerosis.
Hong Kong. Hong Kong has the highest PD utilization rate and PD PMP rate in the world, with nearly 80% and 489, respectively [1] . This is largely due to the PD first policy, and also helped by the fact that PD is less than half as expensive as HD.
Singapore. Singapore has a PD utilization rate of nearly 19%. The overall dialysis PMP is 842, out of which 684 is HD PMP and 158 is the PD PMP [1] . The government of Singapore offers the same reimbursement for both modalities. The HD/PD cost ratio is 1.38 [16] .
Vietnam. The number of patients on PD in Vietnam has increased considerably between 2003 (42 PD patients) and 2008 (1007 PD patients). Like China, the PD growth is much attributed to economic growth and enthusiasm of nephrologists rather than government intervention. According to a paper by Van Bui [17] in 2008, the cost of PD may be slightly less than that of HD. The HD/PD ratio resulting from that assumption is slightly >1.00.
Philippines. Philippines has a PD utilization rate of ∼12.5%. The number of patients on PD in 2008 was 952 [1] . According to a paper by Naidas et al. [18] in 1998, the cost of PD was less than that of HD with a HD/PD ratio of ∼1.14.
Australia. Australia has a PD utilization rate of nearly 23%. The overall dialysis PMP is 465 [1] with a HD PMP of 360, and a PD PMP of 105. Low population density in several parts of the country could possibly contribute to higher PD utilizations, because of longer distances to HD clinics. The HD/PD ratio is also in favour of PD, with a value of 1.44 which was calculated from a paper by Howard et al. [19] .
New Zealand. New Zealand has a PD utilization rate >36%. The overall PMP is 503, with 320 being the HD PMP and 183 being the PD PMP [1] . A HD/PD ratio of 1.58 favours greater use of PD (Ashton et al. [20] ).
CO N C L U S I O N
From our results, we can clearly see that PD is a more affordable modality in most countries. This conclusion is further corroborated by the fact that some cases (i.e. the basic cost assessments) do not consider the hidden costs like loss of productivity of patient and his family members and cost of transportation to the centre. For this reason, any possible bias deriving from the measurement error in costs is likely to underestimate-and not overestimate-the cost advantage of PD over HD. In some developing countries like Sudan and India, patients receive only twice weekly HD sessions instead of thrice weekly HD sessions due to prohibitive costs. We should take this into consideration when we are looking at the relative costs. Again, this factor will lead to lower estimates for the overall cost ratio. The actual HD/PD ratios might be higher than the ones reported in this article. For these reasons, such measurement errors deriving from heterogeneous methodologies (which are quite possibly present in this literature) do not invalidate our conclusion that PD is overall more cost-effective than HD.
There was just one case (India) in which we needed to adjust the HD/PD cost ratio since it was originally calculated for thrice daily CAPD exchange versus thrice weekly HD sessions. The final estimate reported in the tables accounts instead for four daily exchanges of CAPD versus thrice weekly HD sessions.
It is clear from our results that the HD/PD cost ratio varies significantly across countries. A thorough investigation of the determinants of such heterogeneity falls beyond the scope of this paper. However, we present some insight into some factors that might contribute to this variability. In Figure 2 , we have included scatterplots that relate each country's HD/PD cost ratio to its Human Development Index, the percentage of healthcare expenditure which is private and the number of PD patients adjusted for population (PDPMP) [1] . All three of these variables seem to bear a very significant correlation with our estimated ratios, which is evident from the r and P values. In Figure 3 , we show that in countries with access to low-cost PD equipment-either through local manufacturing or through low import duties-PD is on average significantly less expensive than HD (see figures for data source references). A more thorough and in-depth analysis of such dynamics is left for future research.
From a macroeconomic standpoint, we can see that increasing PD utilization rates in developed countries (where PD is significantly less expensive than HD) can help reduce the overall healthcare expenditure. Currently, the USA spends nearly 18% [21] of its GDP on healthcare (far higher than the Organisation for Economic Cooperation and Development member countries average of 9.5% [21] ). A paper by Neil et al. [22] in 2009 argued that the USA could realize aggregated savings of over USD 1.1 billion in 5 years just on Medicare costs if PD utilization were increased to 15% (from the current 7%). Another example from the literature is an abstract by Chen et al. [23] in 2007, talking about potential savings achievable through a similar strategy in Singapore. It concludes by saying that an increase in PD utilization from 21 to 40% could result in a 5-year cumulative saving of nearly USD 25 million.
Another advantage connected to PD is that it is not as dependent on infrastructure and geography as HD is. cannot provide HD to some patients because of unfavourable geographical dispersion could possibly consider PD as an alternative.
As we have shown before, market factors seem to play a major role in PD utilization. Governments should realize that the bulk of PD costs arise from the market price of the CAPD bags. It has been observed that the market for CAPD bags in most countries is monopolistic; this tends to drive up market prices. It is a government prerogative to impose price controlling strategies, so that ESRD patients can access medical supplies at a reasonable cost. For example, this can be achieved by reducing the import duty levied on PD materials. This will also have the benefit of progressively reducing prices, since lowering the barriers to trade allows more than one foreign producer to compete on the national market at the same time, and also to take advantage of larger economies of scale.
In the end, PD utilization can be effectively promoted by governments; some examples include the implementation of a PD first programme (as was done by Thailand recently), the encouragement of local manufacturing or production of CAPD bags (done by India over the last decade) and the slashing of import duties on CAPD bags (as has been done in Nepal and Malaysia).
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